Background: To report on the first multicenter Italian experience with rufinamide as adjunctive drug in children, adolescents and young adults with refractory childhood-onset epileptic encephalopathies other than Lennox-Gastaut syndrome.Methods: Thirty-eight patients (19 males, 19 females), aged between 4 and 34 (mean 13.7± 8.3, median 12.5), all affected by different types of childhood-onset refractory epileptic encephalopathies other than Lennox-Gastaut syndrome, were treated with rufinamide as adjunctive drug for a mean period of 11.4 months (range 3-26 months).Results: Fifteen of 38 patients (39.5%) had a >50% seizure reduction in countable seizures. Complete seizure freedom was achieved in one of these patients (2.6%). Three patients (7.9%) had a 25-49% seizure reduction, whilst seizure frequency remained unchanged in 15 (39.5%) and increased in five patients (13.1%). Eleven patients (28.9%) reported adverse side effects. Vomiting was reported in five patients (13.1%); drowsiness, decreased appetite and irritability with migraine manifested in other four patients. They were transient and mild in all cases.Conclusion: Rufinamide may be an effective and well-tolerated adjunctive drug for the treatment of refractory childhood-onset epileptic encephalopathies other than Lennox-Gastaut syndrome. Rufinamide was most effective in patients with drop-attacks and (bi)frontal spike-wave discharges.

Coppola, G., Grosso, S., Franzoni, E., Veggiotti, P., Zamponi, N., Parisi, P., et al. (2011). Rufinamide in refractory childhood epileptic encephalopathies other than Lennox-Gastaut syndrome. EUROPEAN JOURNAL OF NEUROLOGY, 18(2), 246-251 [10.1111/j.1468-1331.2010.03113.x].

Rufinamide in refractory childhood epileptic encephalopathies other than Lennox-Gastaut syndrome

Grosso, S.;
2011-01-01

Abstract

Background: To report on the first multicenter Italian experience with rufinamide as adjunctive drug in children, adolescents and young adults with refractory childhood-onset epileptic encephalopathies other than Lennox-Gastaut syndrome.Methods: Thirty-eight patients (19 males, 19 females), aged between 4 and 34 (mean 13.7± 8.3, median 12.5), all affected by different types of childhood-onset refractory epileptic encephalopathies other than Lennox-Gastaut syndrome, were treated with rufinamide as adjunctive drug for a mean period of 11.4 months (range 3-26 months).Results: Fifteen of 38 patients (39.5%) had a >50% seizure reduction in countable seizures. Complete seizure freedom was achieved in one of these patients (2.6%). Three patients (7.9%) had a 25-49% seizure reduction, whilst seizure frequency remained unchanged in 15 (39.5%) and increased in five patients (13.1%). Eleven patients (28.9%) reported adverse side effects. Vomiting was reported in five patients (13.1%); drowsiness, decreased appetite and irritability with migraine manifested in other four patients. They were transient and mild in all cases.Conclusion: Rufinamide may be an effective and well-tolerated adjunctive drug for the treatment of refractory childhood-onset epileptic encephalopathies other than Lennox-Gastaut syndrome. Rufinamide was most effective in patients with drop-attacks and (bi)frontal spike-wave discharges.
2011
Coppola, G., Grosso, S., Franzoni, E., Veggiotti, P., Zamponi, N., Parisi, P., et al. (2011). Rufinamide in refractory childhood epileptic encephalopathies other than Lennox-Gastaut syndrome. EUROPEAN JOURNAL OF NEUROLOGY, 18(2), 246-251 [10.1111/j.1468-1331.2010.03113.x].
File in questo prodotto:
File Dimensione Formato  
Coppola_Ruf_in_other_than_LGS_2011.pdf

non disponibili

Tipologia: PDF editoriale
Licenza: PUBBLICO - Pubblico con Copyright
Dimensione 76.01 kB
Formato Adobe PDF
76.01 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/1095772
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo